Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 14, 2016

Zealand Pharma begins Phase IIa trial of dasiglucagon in artificial pancreas system to treat hypoglycaemia

Denmark-based Zealand Pharma (Zealand) has begun its Phase IIa clinical trial of dasiglucagon in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics for hypoglycaemia.

Denmark-based Zealand Pharma (Zealand) has begun its Phase IIa clinical trial of dasiglucagon in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics for hypoglycaemia.

Dasiglucagon is an analogue of peptide hormone human glucagon, which is produced by alpha cells of the pancreas and released to prevent blood glucose levels dropping low, thereby ensuring a well-functioning metabolic system.

The multiple-dose version of dasiglucagon is aimed to be used in a dual-hormone artificial pancreas system to better manage hypoglycaemia and offer easier options to insulin treated diabetes patients for effective management of their disease.

A dual-hormone artificial (or bionic) pancreas system, designed to automatically deliver insulin and glucagon to people with type 1 diabetes, copies the function of a healthy pancreas.

The Phase IIa trial is the fourth Phase II trial initiated by Zealand this year that intends to determine the safety, efficacy and tolerability of dasiglucagon as part of the Beta Bionics dual-hormone artificial (bionic) pancreas system in adult patients with type 1 diabetes, compared to a recombinant market glucagon.

"The Phase IIa trials are expected to pave the way for longer clinical trials, with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system."

The company previously entered into collaboration with Beta Bionics, which is developing the dual-hormone artificial (bionic) pancreas system based on technology conceived at Boston University.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The trial's principal investigator Steven Russell said: “This Phase IIa study will test the effectiveness of the stable glucagon analogue dasiglucagon in the dual-hormone bionic pancreas, comparing it with the unstable glucagon formulation that we have used in all of our previous studies.

“Demonstrating the effectiveness of a stable glucagon formulation or analogue, such as dasiglucagon, is an essential step towards making a dual-hormone bionic pancreas available to patients."

The Phase IIa trials are expected to pave the way for longer clinical trials, with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system.

Results from both trials are expected in the first quarter of next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU